Evotec

EVO

Market cap $1.28B

Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years HAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies, called "J.MD™". Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.

Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / January 2, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec's newly integrated Global Communications and Investor Relations function.

Evotec remains a speculative 'buy' with a maintained share price target, reflecting deep undervaluation despite a >50% market cap decline. EVO's biologics segment shows positive EBITDA and 11% growth, but the larger Discovery segment remains weak, down 12% in 3Q25. Positive free cash flow, reduced leverage, and a robust partner pipeline ($200M+ in signed orders) support fundamental safety, with no imminent bankruptcy risk.

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platform In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years,replacing existing contractual commitments Transaction covering royalties on a portfolio ofup to ten biosimilars in technical and early development targetingmore than US$ 90 bn of originator net sales Sale immediately earnings accretive, improving Evotec's short, mid and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / ACCESS Newswire / December 8, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the closing of its previously reported sale of the Just - Evotec Biologics Toulouse site plus an indefinite technology license to Evotec's continuous manufacturing platform technology to Sandoz AG (SIX:SDZ / OTCQX:SDZNY), effective 05 December 2025. In total, potential payments may exceed US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules, of which six have an originator net sales value of US$ 90 bn.

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS Newswire / December 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that its partner Bayer AG has initiated a Phase 2 clinical study of a kidney disease program originating from the multi-target research collaboration between Evotec and Bayer in kidney diseases. Under the terms of the collaboration agreement, Evotec is eligible to receive a milestone payment upon first patient dosing, which is expected in early 2026.

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that it has received a US$ 5 m milestone payment from Bristol Myers Squibb, following the acceptance of an Investigational New Drug ("IND") application by the U.S. Food and Drug Administration ("FDA") in their strategic protein degradation partnership. The drug candidate, a cereblon E3 ligase modulator ("CELMoD™") was developed under the collaboration, and a Phase 1 clinical trial is expected to begin in 2026.

Evotec SE ( EVO ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Volker Braun - Executive VP and Head of Global Investor Relations & ESG Christian Wojczewski - CEO & Management Board Member Paul Hitchin - CFO & Member of Management Board Cord Dohrmann - Chief Scientific Officer & Member of Management Board Conference Call Participants Charles Weston - RBC Capital Markets, Research Division Brendan Smith - TD Cowen, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Presentation Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement 9M 2025 Conference Call. I'm Lorenzo, the Chorus Call operator.

Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business Strong scientific advancements of co-developed asset pipeline: Expecting up to four molecules in clinical phase II in next six to nine months Signing of landmark industry transaction with Sandoz on 04 November, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules 2025 guidance and 2028 outlook confirmed HAMBURG, DE / ACCESS Newswire / November 5, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced its business update for 9M 2025, illustrating the ongoing systematic execution of its strategy. In the D&PD segment, the market for early drug discovery services remained soft, while strategic partnerships are on track and Evotec records strong progress in its partnered asset pipeline.

Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business model Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platform In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years, replacing existing contractual commitments Transaction covering royalties on a portfolio of up to ten biosimilars in technical and early development targeting more than US$ 90 bn of originator net sales Sale immediately earnings accretive, improving Evotec's short, mid and long-term revenue mix, profit margins, and capital efficiency HAMBURG, GERMANY / ACCESS Newswire / November 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO), a life science company that is pioneering the future of drug discovery and development, today announced the successful signing of the sale of the Just - Evotec Biologics Toulouse site to Sandoz AG (SIX:SDZ)(OTCQX:SDZNY), a global leader in generic and biosimilar medicines. Under the landmark transaction, Sandoz will acquire 100% of Just - Evotec Biologics EU plus an indefinite technology license to Evotec's continuous manufacturing platform technology for a payment of approximately US$ 350 m in cash.

HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.